Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 4
1988 5
1989 2
1990 1
1991 2
1992 1
1994 2
1995 1
1996 3
1997 1
1998 1
1999 3
2000 2
2001 2
2002 1
2004 3
2005 2
2006 2
2007 6
2008 4
2009 7
2010 8
2011 4
2012 13
2013 8
2014 9
2015 11
2016 10
2017 9
2018 6
2019 4
2020 3
2021 5
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
[Neurology].
Chopard I, Benninger D, Demonet JF, Du Pasquier R, Hirt L, Kuntzer T, Michel P, Nater B, Novy J, Rossetti A, Rouaud O, Ryvlin P, Schluep M, Theaudin M. Chopard I, et al. Among authors: schluep m. Rev Med Suisse. 2018 Jan 10;14(588-589):58-61. Rev Med Suisse. 2018. PMID: 29337452 French.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. Kappos L, et al. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Free article. Clinical Trial.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group. Disanto G, et al. Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954. Ann Neurol. 2017. PMID: 28512753 Free PMC article.
[Neurology].
Maulucci F, Benninger D, Démonet JF, Du Pasquier RA, Hirt L, Hottinger A, Kuntzer T, Michel P, Nater B, Novy J, Rossetti AO, Schluep M, Vingerhoets FJG. Maulucci F, et al. Among authors: schluep m. Rev Med Suisse. 2017 Jan 11;13(544-545):79-83. Rev Med Suisse. 2017. PMID: 28703543 Review. French.
[Neurology].
Chabwine JN, Rossetti AR, Hirt L, Kuntzer T, Schluep M, Michel P, Démonet JF, du Pasquier RA, Vingerhoets FG. Chabwine JN, et al. Among authors: schluep m. Rev Med Suisse. 2012 Jan 11;8(323):46-50. Rev Med Suisse. 2012. PMID: 22303740 French.
Assessing risks of multiple sclerosis therapies.
Parfenov V, Schluep M, Du Pasquier R. Parfenov V, et al. Among authors: schluep m. J Neurol Sci. 2013 Sep 15;332(1-2):59-65. doi: 10.1016/j.jns.2013.06.013. Epub 2013 Jul 5. J Neurol Sci. 2013. PMID: 23835089 Review.
[Communication about in hospital resuscitation orders].
Schluep M, Hoeks SE, Endeman HR, IJmkers S, Romijn TMM, Alsma J, Bosch FH, Cornet AD, Knook AHMM, Koopman-van Gemert AWMM, van Melsen T, Peters R, Simons KS, Wils EJ, Stolker RJ, van Dijk M. Schluep M, et al. Ned Tijdschr Geneeskd. 2021 Apr 29;165:D5692. Ned Tijdschr Geneeskd. 2021. PMID: 34346627 Dutch.
Author Response.
Du Pasquier RA, Canales M, Schluep M. Du Pasquier RA, et al. Among authors: schluep m. Neurology. 2013 Jul 2;81(1):98. Neurology. 2013. PMID: 23980272 No abstract available.
139 results